Meeting
2023 ASCO Annual Meeting
Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction (PCR) versus next-generation sequencing (NGS) testing strategies in metastatic non-small cell lung cancer (mNSCLC).
Authors
Christine M. Bestvina
University of Chicago, Chicago, IL
Christine M. Bestvina , Dexter Waters , Laura Morrison , Bruno Emond , Marie-Hélène Lafeuille , Annalise Hilts , Patrick Lefebvre , Andy He , Julie Vanderpoel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Health Services Research and Quality Improvement
Track
Quality Care/Health Services Research
Sub Track
Value/Cost of Care
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 6638)
DOI
10.1200/JCO.2023.41.16_suppl.6638
Abstract #
6638
Poster Bd #
130
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Detection of comprehensive oncogenic driver alteration of non-small cell lung cancer from cytology specimens by multi-gene PCR panel.
First Author: Tetsuya Sakai
Poster
2023 ASCO Annual Meeting
Survival associations and driver oncogene overlap for copy-number amplifications of ERBB2, KRAS and MET in non-small cell lung cancer.
First Author: Alexander Watson
Poster
2023 ASCO Annual Meeting
Caveat emptor: A descriptive analysis of guideline-recommended biomarker inclusion in targeted NGS panels for metastatic non-small cell lung cancer (mNSCLC).
First Author: John Leonard Fox
Poster
2023 ASCO Annual Meeting
Response to neoadjuvant immune checkpoint inhibitor (ICI)-based therapy in oncogene-driven resectable non-small cell lung cancer (NSCLC).
First Author: Samuel Rosner